TIL Therapy for Cervical Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma
Will I have to stop taking my current medications?
The trial requires that any prior therapy directed at the tumor, including chemotherapy, biologic/targeted agents, and immunologic agents, must be stopped at least 28 days before tumor resection. If you are on these types of medications, you will need to stop them before participating.
Is TIL therapy safe for humans?
How is TIL therapy for cervical cancer different from other treatments?
TIL therapy for cervical cancer is unique because it uses a patient's own immune cells, specifically tumor-infiltrating lymphocytes, to target and kill cancer cells, offering a personalized treatment approach. Unlike traditional therapies, it involves a modified lymphodepleting regimen that reduces severe side effects, and it has shown promising results in achieving complete response in some patients.26789
What data supports the effectiveness of this treatment for cervical cancer?
Research shows that tumor-infiltrating lymphocyte (TIL) therapy, which involves using a patient's own immune cells to fight cancer, has shown promising results in treating cervical cancer. In one case, a patient with recurrent cervical cancer achieved complete response after receiving TIL therapy, indicating its potential effectiveness.267910
Who Is on the Research Team?
Iovance Medical Monitor
Principal Investigator
Iovance Biotherapeutics, Inc.
Are You a Good Fit for This Trial?
Adults over 18 with recurrent, metastatic, or persistent cervical cancer not treatable by surgery/radiation. Must have measurable lesions and be in good physical condition (ECOG 0-1). Previous systemic therapy is required; however, no more than three lines of chemotherapy for Cohorts 1 and 2. Participants must have adequate organ function, no active infections or HIV, and agree to contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepletion
Participants receive a non-myeloablative lymphodepleting preparative regimen
Treatment
Participants are infused with autologous TIL (LN-145) followed by IL-2 administration
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LN-145
- Pembrolizumab
LN-145 is already approved in United States for the following indications:
- Cervical Cancer
- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Non-Small Cell Lung Cancer (NSCLC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Iovance Biotherapeutics, Inc.
Lead Sponsor